Literature DB >> 32715940

Homology modeling and in silico design of novel and potential dual-acting inhibitors of human histone deacetylases HDAC5 and HDAC9 isozymes.

Ammar D Elmezayen1, Kemal Yelekçi1.   

Abstract

Histone deacetylases (HDACs) are a group of enzymes that have prominent and crucial effect on various biological systems, mainly by their suppressive effect on transcription. Searching for inhibitors targeting their respective isoforms without affecting other targets is greatly needed. Some histone deacetylases have no crystal structures, such as HDAC5 and HDAC9. Lacking proper and suitable crystal structure is obstructing the designing of appropriate isoform selective inhibitors. Here in this study, we constructed human HDAC5 and HDAC9 protein models using human HDAC4 (PDB:2VQM_A) as a template by the means of homology modeling approach. Based on the Z-score of the built models, model M0014 of HDAC5 and model M0020 of HDAC9 were selected. The models were verified by MODELLER and validated using the Web-based PROCHECK server. All selected known inhibitors displayed reasonable binding modes and equivalent predicted Ki values in comparison to the experimental binding affinities (Ki/IC50). The known inhibitor Rac26 showed the best binding affinity for HDAC5, while TMP269 showed the best binding affinity for HDAC9. The best two compounds, CHEMBL2114980 and CHEMBL217223, had relatively similar inhibition constants against HDAC5 and HDAC9. The built models and their complexes were subjected to molecular dynamic simulations (MD) for 100 ns. Examining the MD simulation results of all studied structures, including the RMSD, RMSF, radius of gyration and potential energy suggested the stability and reliability of the built models. Accordingly, the results obtained in this study could be used for designing de novo inhibitors against HDAC5 and HDAC9. Communicated by Ramaswamy H. Sarma.

Entities:  

Keywords:  HDAC5; HDAC9; MD simulation; homology model; known inhibitors; molecular docking; virtual screening

Mesh:

Substances:

Year:  2020        PMID: 32715940     DOI: 10.1080/07391102.2020.1798812

Source DB:  PubMed          Journal:  J Biomol Struct Dyn        ISSN: 0739-1102


  5 in total

1.  Identification of potential plant-based inhibitor against viral proteases of SARS-CoV-2 through molecular docking, MM-PBSA binding energy calculations and molecular dynamics simulation.

Authors:  Bhaskarjyoti Gogoi; Purvita Chowdhury; Nabajyoti Goswami; Neelutpal Gogoi; Tufan Naiya; Pankaj Chetia; Saurov Mahanta; Dipak Chetia; Bhaben Tanti; Probodh Borah; Pratap Jyoti Handique
Journal:  Mol Divers       Date:  2021-04-15       Impact factor: 3.364

2.  Computational investigation of drug bank compounds against 3C-like protease (3CLpro) of SARS-CoV-2 using deep learning and molecular dynamics simulation.

Authors:  Tushar Joshi; Priyanka Sharma; Shalini Mathpal; Tanuja Joshi; Priyanka Maiti; Mahesha Nand; Veena Pande; Subhash Chandra
Journal:  Mol Divers       Date:  2021-10-12       Impact factor: 3.364

Review 3.  An Updated Review of Computer-Aided Drug Design and Its Application to COVID-19.

Authors:  Arun Bahadur Gurung; Mohammad Ajmal Ali; Joongku Lee; Mohammad Abul Farah; Khalid Mashay Al-Anazi
Journal:  Biomed Res Int       Date:  2021-06-24       Impact factor: 3.411

4.  Seq12, Seq12m, and Seq13m, peptide analogues of the spike glycoprotein shows antiviral properties against SARS-CoV-2: An in silico study through molecular docking, molecular dynamics simulation, and MM-PB/GBSA calculations.

Authors:  Kunal Dutta; Ammar D Elmezayen; Anas Al-Obaidi; Wei Zhu; Olga V Morozova; Sergey Shityakov; Ibrahim Khalifa
Journal:  J Mol Struct       Date:  2021-07-16       Impact factor: 3.196

5.  Using Chou's 5-steps rule to study pharmacophore-based virtual screening of SARS-CoV-2 Mpro inhibitors.

Authors:  Hemlata Pundir; Tanuja Joshi; Tushar Joshi; Priyanka Sharma; Shalini Mathpal; Subhash Chandra; Sushma Tamta
Journal:  Mol Divers       Date:  2020-10-20       Impact factor: 3.364

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.